CN113395966A - 用于治疗脑瘫中的运动障碍的方法 - Google Patents

用于治疗脑瘫中的运动障碍的方法 Download PDF

Info

Publication number
CN113395966A
CN113395966A CN201980089635.4A CN201980089635A CN113395966A CN 113395966 A CN113395966 A CN 113395966A CN 201980089635 A CN201980089635 A CN 201980089635A CN 113395966 A CN113395966 A CN 113395966A
Authority
CN
China
Prior art keywords
patient
baseline
score
patients
deutetrabenazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980089635.4A
Other languages
English (en)
Chinese (zh)
Inventor
尤哈-马蒂·萨沃纳
马克·福里斯特·戈登
弗兰克·施耐德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ospex Pharmaceuticals
Original Assignee
Ospex Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ospex Pharmaceuticals filed Critical Ospex Pharmaceuticals
Publication of CN113395966A publication Critical patent/CN113395966A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980089635.4A 2018-12-13 2019-12-13 用于治疗脑瘫中的运动障碍的方法 Pending CN113395966A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779232P 2018-12-13 2018-12-13
US62/779,232 2018-12-13
US201962801450P 2019-02-05 2019-02-05
US62/801,450 2019-02-05
PCT/US2019/066150 WO2020123900A1 (en) 2018-12-13 2019-12-13 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy

Publications (1)

Publication Number Publication Date
CN113395966A true CN113395966A (zh) 2021-09-14

Family

ID=69173404

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980089635.4A Pending CN113395966A (zh) 2018-12-13 2019-12-13 用于治疗脑瘫中的运动障碍的方法

Country Status (15)

Country Link
US (3) US11324732B2 (https=)
EP (1) EP3893876A1 (https=)
JP (1) JP2022519007A (https=)
KR (1) KR20210114946A (https=)
CN (1) CN113395966A (https=)
AU (1) AU2019395250A1 (https=)
BR (1) BR112021011386A2 (https=)
CA (1) CA3123393A1 (https=)
CL (1) CL2021001554A1 (https=)
IL (1) IL283920A (https=)
MX (1) MX2021007063A (https=)
SG (1) SG11202106344SA (https=)
TW (1) TWI784220B (https=)
WO (1) WO2020123900A1 (https=)
ZA (1) ZA202104786B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210114946A (ko) * 2018-12-13 2021-09-24 오스펙스 파마슈티칼스, 인코포레이티드 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진
BR112023021257A2 (pt) * 2021-04-15 2023-12-12 Neurocrine Biosciences Inc Métodos para a administração combinada de deutetrabenzina e um cyp2d6
WO2022221551A1 (en) * 2021-04-15 2022-10-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
WO2024090922A1 (ko) 2022-10-24 2024-05-02 주식회사 디자인셀 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100130480A1 (en) * 2008-09-18 2010-05-27 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2015200243A1 (en) * 2009-06-24 2015-02-12 Egalet Ltd Controlled release formulations
CN107624067A (zh) * 2015-03-06 2018-01-23 奥斯拜客斯制药有限公司 用于治疗异常不自主运动障碍的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351247A1 (en) * 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
PE20191819A1 (es) 2017-03-15 2019-12-27 Auspex Pharmaceuticals Inc Analogos de deutetrabenazina, su preparacion y uso
KR20210114946A (ko) * 2018-12-13 2021-09-24 오스펙스 파마슈티칼스, 인코포레이티드 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100130480A1 (en) * 2008-09-18 2010-05-27 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2015200243A1 (en) * 2009-06-24 2015-02-12 Egalet Ltd Controlled release formulations
CN107624067A (zh) * 2015-03-06 2018-01-23 奥斯拜客斯制药有限公司 用于治疗异常不自主运动障碍的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANJAN CHATTERJEE ET AL: "Tetrabenazine in the Treatment of Severe Pediatric Chorea", 《MOVEMENT DISORDERS》, vol. 18, pages 703 - 706 *
MARTIN SMITH ET AL: "The challenge of dyskinetic cerebral palsy", 《DEVELOPMENTAL MEDICINE & CHILD NEUROLOGY》, vol. 54 *
张和振: "《实用神经内科学 症候与疾病》", 中国科学技术出版社, pages: 741 *

Also Published As

Publication number Publication date
US20200188371A1 (en) 2020-06-18
US20220409597A1 (en) 2022-12-29
CL2021001554A1 (es) 2022-02-11
WO2020123900A1 (en) 2020-06-18
EP3893876A1 (en) 2021-10-20
ZA202104786B (en) 2023-12-20
US20240082225A1 (en) 2024-03-14
CA3123393A1 (en) 2020-06-18
US11324732B2 (en) 2022-05-10
IL283920A (en) 2021-07-29
AU2019395250A1 (en) 2021-07-29
TWI784220B (zh) 2022-11-21
MX2021007063A (es) 2021-12-10
JP2022519007A (ja) 2022-03-18
TW202034917A (zh) 2020-10-01
BR112021011386A2 (pt) 2021-08-31
SG11202106344SA (en) 2021-07-29
KR20210114946A (ko) 2021-09-24

Similar Documents

Publication Publication Date Title
US20250302851A1 (en) Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
ES2879631T3 (es) Pridopidina para el tratamiento de la enfermedad de Huntington
US20230093150A1 (en) Changing cognitive function with fenfluramine
US20240082225A1 (en) Methods for the treatment of dyskinesia in cerebral palsy
JP2026050474A (ja) Ｎｍｄａ拮抗薬の副作用の低減
TW201707700A (zh) 以加波沙朵（ｇａｂｏｘａｄｏｌ）治療發育障礙的方法
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
CN113825510A (zh) 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法
RU2768894C2 (ru) Применение обратного агониста h3r для лечения расстройства сна при сменной работе
CN118555956A (zh) 用于治疗难治性抑郁症的赛洛西宾和辅助血清素再摄取抑制剂
Babu et al. Birth weight and use of olanzapine in pregnancy: a prospective comparative study
CN108451953A (zh) 利用氨基吡啶治疗中风相关的感觉运动损伤的方法
CN121013719A (zh) 治疗特发性震颤的方法
EA044015B1 (ru) Дейтетрабеназин для лечения дискинезии при церебральном параличе
US20250375417A1 (en) Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1)
EP4618973A1 (en) Methods of switching neuropsychiatric medications using ulotaront
Aggarwal et al. Akathisia associated with mianserin
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
Mowla et al. Topiramate for bruxism: report of 2 cases
CN118488843A (zh) 用赛洛西宾治疗难治性抑郁症
Singh et al. 3447 Effects of intranasal ketamine on uncontrolled cancer related pain
BA A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa
Shapiro et al. Comments on" Delayed Loss of Efficacy and Depressogenic Action of Antidepressants"
Raja Reply to Comments by Drs Shapiro and Verma: Posttreatment, Refractory Depression

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination